
[ad_1]
LIMA, Peru–(BUSINESS WIRE)–We are very pleased to announce that the Peruvian General Directorate of Drugs, Supplies and Medicines (DIGEMID) has approved ORLADEYO® (berotralstat), a daily oral medication, for the prevention of episodes of hereditary angioedema (HAE) in adults and children 12 years and older.
Hereditary angioedema is an inherited disease that causes recurring, sudden, painful swelling of the skin, mucous membranes, and submucosal tissues. Until recently, treatment options for HAE were limited, resulting in patients suffering from a compromised quality of life and a constant risk of severe attacks.
“The approval of Orladeyo by Digitime is great news for the Peruvian hereditary angioedema patient community,” commented Dr. Valnei Canutti, Scientific Director of Pint Pharma. “This innovative oral therapy is a breakthrough for people living with this rare disease, providing an effective and convenient long-term preventive option to prevent attacks of hereditary angioedema.”
“In addition to providing direct benefits to patients, the launch of Orladeyo in Peru highlights our ongoing commitment to advancing research and innovation in rare disease healthcare,” said David Muñoz, CEO of Pint Pharma.
“The approval of Orladeyo is a great achievement for patients and a testament to the successful collaboration between the Peruvian medical community, regulators and pharmaceutical companies to improve treatment options,” said Mauricio Botero, General Manager of Pint Pharma, Latin America North Cluster.
About Oladeyo
ORLADEYO® (berotralstat) is the first and only oral therapy specifically indicated for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. One ORLADEYO capsule per day prevents HAE attacks by reducing the activity of plasma kallikrein. ORLADEYO is a product of BioCryst Pharmaceuticals, Inc., with registration, marketing and distribution managed exclusively by Pint Pharma in Latin America.
About Pinte Pharmaceuticals
Pint Pharma, headquartered in Vienna, Austria, is a pharmaceutical company specializing in the acquisition or licensing and marketing of pharmaceutical products for Latin America. We are a community-focused company that prides itself on providing exceptional experience and knowledge of the Latin American pharmaceutical industry, striving to provide people with the best treatments and services through strategic alliances with global business partners.
Contact information
Jorge Camacho
Head of Strategy and Portfolio Strategy
e-mail: (email protected)
Valne Canuti
Chief Scientific Officer
e-mail: (email protected)
window.fbAsyncInit = function() { FB.init({
appId : '808710783748256',
xfbml : true, version : 'v2.9' }); };
(function(d, s, id){
var js, fjs = d.getElementsByTagName(s)(0);
if (d.getElementById(id)) {return;}
js = d.createElement(s); js.id = id;
js.src = "https://connect.facebook.net/en_US/sdk.js";
fjs.parentNode.insertBefore(js, fjs);
}(document, 'script', 'facebook-jssdk'));
[ad_2]
Source link